Scientists Can License a Mouse Tumor That Outsmarts Immunotherapy
Published Date: 8/12/2026
Notice
Summary
The National Cancer Institute has created a special mouse colon cancer cell line that resists popular cancer immunotherapies. This new tool helps scientists study why some tumors dodge treatment and test better ways to fight them. Researchers and companies can now license this invention to speed up cancer therapy breakthroughs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
MC38 B2m KO Cell Line Available for License
The National Cancer Institute (NCI) is offering a CRISPR/Cas9-engineered MC38 B2m knockout murine colon cancer cell line for licensing (NIH Reference Number E-123-2026-0). Researchers and companies interested in licensing can contact Michael Pollack, Ph.D., at the NCI Technology Transfer Center; this notice was published in the Federal Register on August 12, 2026.
Tool Enables R&D on Checkpoint-Resistant Tumors
The MC38 B2m KO cell line models tumor resistance to PD-1/PD-L1 checkpoint blockade by deleting the B2m gene and causing loss of MHC-I antigen presentation. The notice explicitly lists potential uses: development of therapeutics to overcome PD-1/PD-L1 resistance, pre-clinical screening of alternative or combination immunotherapies, evaluation of therapies for cancers with defective antigen presentation, and use as a companion model against wild-type MC38 tumors.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-21816, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the National Institutes of Health is holding several closed virtual meetings in November 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists applying for grants in areas like molecular protein interactions, infectious disease, and cancer immunotherapy should note these important review dates.
2026-21689, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in November 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding, ensuring their confidential info stays private. No new costs or deadlines are introduced, but these reviews are key steps in funding important scientific projects.
2026-21688, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in November 2026 to review and evaluate grant applications. These meetings affect researchers applying for funding in areas like cardiovascular health, environmental diseases, and nanotechnology. No public access is allowed to protect private info and trade secrets, but these reviews help decide who gets research money.
2026-21527, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in November 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for scientific projects, especially in biophysics, immunology, neurodegenerative disorders, and anti-infective therapies. No public access is allowed to protect private and sensitive information, but these reviews help decide who gets research money.
2026-21526, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings in November 2026 to review and decide on grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for important health research. If you’re involved in health or small business research grants, these reviews could impact your funding timeline and opportunities.
2026-21525, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in November 2026 to review important grant applications related to health research. These meetings protect private info and trade secrets while deciding which projects get funding. Scientists and small businesses applying for grants will be affected, with no changes to timing or money announced.
Previous / Next Documents
Previous: 2026-16448, UChicago Argonne LLC et al; Notice of Decision on Application for Duty-Free Entry of Scientific Instruments
UChicago Argonne LLC and other top research labs got the green light to bring in some super high-tech scientific instruments without paying import duties. These tools, made overseas, help study batteries, cells, and advanced materials—stuff we can’t make here in the U.S. right now. This decision speeds up cutting-edge research without extra costs, helping science move faster and smarter.
Next: 2026-16450, Inbound EMS 2
The Commission is acknowledging a recent Postal Service filing announcing its intention to change prices not of general applicability to be effective January 1, 2027. This document informs the public of the filing, invites public comment, and takes other administrative steps.